酶替代疗法改善了高氏病的红色素形成和铁失调
Irene Motta1,2, Paola Delbini2, Natalia Scaramellini1,2
1Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy.
Annals of hematology
|October 6, 2024
概括
酶替代疗法 (ERT) 改善了高氏病 (GD) 患者的贫血和铁代谢. 正如临床和实体研究表明的,ERT可以增强红细胞的产生和铁的利用.
科学领域:
- 血液学 血液学 血液学
- 溶酶体储存障碍 溶酶体储存障碍
- 铁的新陈代谢 铁的新陈代谢
背景情况:
- 氏病 (GD) 经常表现为贫血和高氏血.
- 巨细胞独立的失血和改变的铁代谢是GD的特征.
- 了解治疗对这些参数的影响对于患者管理至关重要.
研究的目的:
- 评估1型GD患者在诊断时和5年随访期间的血液和铁状况.
- 评估酶替代疗法 (ERT) 对红色素形成和铁利用的影响.
- 通过使用患者衍生细胞,研究ERT对红色素形成的ex vivo影响.
主要方法:
- 1型GD患者的纵向研究,评估诊断时 (T0) 和5年后 (T6) 的血液和铁参数.
- 使用CD34+外周血细胞模拟红色素形成的ex vivo研究.
- 对血红蛋白,GFD15,血清费里丁,转林和 (TSAT),肝素,TFRC,HAMP和SLC40A1表达的分析.
主要成果:
- 在诊断时,41%的患者患有贫血,51%患有高血.
- ERT显著改善了血红蛋白水平,减少了无效红色素形成的标志物 (GFD15),并降低了血清费里丁.
- 在ex vivo模型中,ERT导致TSAT增加,肝激素减少,并恢复了红状腺分化能力,具有改变的铁运输基因表达.
结论:
- 铁的失调显著导致高氏病的贫血.
- 酶替代疗法有效地改善了GD患者的红色素形成和铁代谢.
- 结合临床和活体数据,可以全面了解ERT在GD中对血液形成和铁处理的益处.
关键词:
贫血 贫血 是一种疾病.酶替代疗法是一种酶替代疗法.戈舍氏病是戈舍氏病的一种疾病.过高ferritinemia 过高ferritinemia 过高ferritinemia 过高ferritinemia 过高ferritinemia 过高ferritinemia 过高ferritinemia 过高ferritinemia 过高ferritinemia铁铁铁是什么意思 铁铁铁更多相关视频
08:53Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes
Published on: January 10, 2025
438
10:16In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
8.0K
相关概念视频
Erythropoiesis
4.1K
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
4.1K
Disorders of Erythrocytes
897
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
897
Factors Affecting Erythropoiesis
3.1K
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
3.1K
Lifecycle of Erythrocytes
1.9K
Erythrocytes, also known as red blood cells, constantly move through blood capillaries. As a result, they damage their plasma membrane due to the continuous friction. Typically, after 100 to 120 days, erythrocytes become rigid and fragile as they wear out. As they pass through small vessels in the spleen and liver, they can get trapped and break apart into fragments.
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups....
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups....
1.9K
Bone Marrow Sampling and Transplants
313
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
313
Antiepileptic Drugs: Potassium Channel Activators
149
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
149
